文献速递神经肿瘤脊柱脊髓外科

脊髓弥漫性中线胶质瘤的临床预后因素与分子特征

Clinical Prognostic Factors and Molecular Characteristics of Spinal Cord Diffuse Midline Gliomas.
PubMed 文献 · Neurosurgery · 2025-05-19

该研究描述了46例脊髓弥漫性中线胶质瘤(DMG)患者的临床与分子特征,并分析其预后价值。中位生存时间为16.5个月,胸段肿瘤预后显著优于其他部位(P=.009),根治性切除术患者生存率趋于提高(P=.003),二次手术患者生存率显著提高(P=.022)。组织学IV级预后显著差于II级和III级(P<.001)。

要点

  • 胸段肿瘤预后显著优于其他部位(P=.009)。
  • 根治性切除术患者生存率趋于提高(P=.003)。
  • 组织学IV级预后显著差于II级和III级(P<.001)。

核心结论

  • 研究分析了46例脊髓DMG患者的临床与分子特征及其预后价值,旨在为循证治疗策略提供依据。

研究设计与样本

  • 描述46例脊髓DMG患者的临床与分子特征,采用Cox回归分析和Kaplan-Meier曲线评估预后价值。

主要发现

  • 诊断时平均年龄为30±14岁,男女比例接近2.1:1,中位生存时间为16.5个月。
  • 肿瘤主要发生于胸段脊柱,其预后显著优于其他部位(P=.009)。
  • 接受根治性切除术的患者生存率趋于提高(P=.003)。
  • 接受二次手术的患者生存率显著提高(P=.022)。
  • 组织学II级中位生存43个月,III级16个月,IV级12个月;IV级预后显著差于II级和III级(P<.001)。

关键数值与推荐

  • 胸段(P=.001)和胸腰段(P=.017)节段及全切除术(P=.018)在组织学II级和III级肿瘤患者中显示显著更高的生存率,而组织学IV级肿瘤患者中未观察到这些差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Spinal cord diffuse midline glioma (DMG) is an extremely rare and aggressive tumor, characterized by a poor prognosis. While sharing similarities with brain DMGs, spinal cord DMGs may exhibit distinct clinical and prognostic features. Recognizing these differences is crucial for developing effective treatment strategies tailored to spinal cord DMGs. The objective of this analysis was to evaluate the survival prognosis and the influencing factors associated with spinal cord DMGs. METHODS: This study describes the clinical and molecular features of 46 patients with spinal cord DMG. The prognostic value of these clinical and molecular characteristics was investigated using Cox regression analysis and Kaplan-Meier curves. RESULTS: The average age at diagnosis was 30 ± 14 years, with male-to-female ratio close to 2.1:1. The median survival time of patients was 16.5 months. Tumors predominantly occur in the thoracic spine, and they exhibited a notably superior prognosis than those in other locations ( P = .009). The survival rate of patients undergoing radical resection tended to increase ( P = .003). In addition, patients undergoing a second surgery demonstrated a significant increase in survival rates ( P = .022). Median survival varied among histological grades: 43 months for grade II, 16 months for grade III, and 12 months for grade IV. Patients with histological grade IV had significantly worse prognosis than those with grades II and III ( P < .001). Thoracic ( P = .001) and thoracolumbar ( P = .017) segments and gross total resection ( P = .018) exhibited significantly higher survival rates for patients with histological grades II and III tumor, whereas none were observed for patients with histological grade IV tumor. CONCLUSION: We conducted an analysis of the clinical and molecular features of 46 patients with spinal cord DMG, exploring their prognostic value. This study aims to provide evidence for evidence-based treatment strategies for spinal cord DMG.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Gao C, Su B, Luan G, et al. Clinical Prognostic Factors and Molecular Characteristics of Spinal Cord Diffuse Midline Gliomas. Neurosurgery. 2025. PMID: 40387326. doi:10.1227/neu.0000000000003527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。